Survival and Biomarkers of COVID-19 Patients Treated with Remdesivir and Favipiravir in ICU during the Peak of Pandemic: A Single Center Study in Bangladesh
M. Nasir, R. A. Perveen, M. Murshed, R. Nazneen, K. A. Talha
Journal of Pharmaceutical Research International · pp. 14–22 · Published 30 Jan 2021
10.9734/jpri/2020/v32i4531088Abstract
Since the first detection of a cluster of COVID-19 patients in China in late 2019, it becomes a global concern due to its transmissibility and ability to progress patients in severe respiratory failure and acute respiratory distress syndrome, which need intensive care unit support for a long time. We observed the repurposing use of remdesivir and favipiravir whether considered as a therapeutic option or not through survival rate and changes in biomarker during 10-day treatment stay in ICU. The retrospective observational study in a tertiary care hospital dedicated to COVID-19 at Dhaka, Bangladesh was done at the peak of COVID-19 pandemic in Bangladesh. The mortality rate, length of ICU stays and eight prognostic biomarkers of patients treated with remdesivir and favipiravir was observed as one of the first ever reported experience in Bangladesh. Among the critically ill patients in ICU, 26 (44.8%) died and 32 (55.2%) were cured during the study period and highest mean duration of stay in ICU was observed (14.33 days and 18.13 days) in FPV-treated patients. Mean of means for all biomarkers CRP (26.0) and d-Dimer (2.64) was recorded higher in favipiravir treated patients in death cases, but NLR, d-NLR, platelet, PLR was much higher in remdesivir treated patient of both death and improved cases. Though overall outcome variables between death and improved cases were not statistically significant (p<0.39) The severity of disease progression in critically ill COVID-19 patients in ICU depends on comorbidities and hyper-responsive inflammatory or immunological biomarkers to predict. Though the emergency use authorization and repurposing use of different antivirals are still on trial, but remdesivir and favipiravir revealed not much hope in improving prognostic biomarkers, survival rate and disease progression at the peak of pandemic in Bangladesh.
Cited by 16
Seyede Nafise Tabatabaei, Zahra Keykhaee, Saghi Nooraei · Drugs and Drug Candidates · 2025
Chui-Zhe Chen, Junde Fang, Shu Chen · BMC Infectious Diseases · 2023
Linda W. A. Rotty, Decky Andrea, Fujiyanto Fujiyanto · e-CliniC · 2023
M. Mahmud, M. Aunkor, F. Rahman · Journal of Clinical and Experimental Investigations · 2023
Amal Almutairi, M. Z. El-Readi, M. Althubiti · Tropical Medicine and Infectious Disease · 2023
Hooman Behboodikhah, E. Shorafa, I. Karimzadeh · Iranian Journal of Science and Technology, Transactions A: Science · 2022
Nadia Y. Islam, S. Mirza, M. Nasir · Asian Journal of Research in Infectious Diseases · 2022
P. Reddy, Saiprasad Patil, Akash Khobragade · International Journal of General Medicine · 2022
A. Mechineni, Hagar Kassab, R. Manickam · Expert Opinion on Drug Safety · 2021
Perveen Ra, N. M, F. J · Global Journal of Medical Research · 2021
Related research
- Impact of COVID -19 on Gallstones Patients — shares topic coverage
- Analyzing the Effect of Lockdown on Weather Parameters Amid COVID-19 Pandemic of Mid Hill Region of Rajouri District of Jammu & Kashmir, Union Territory, India — shares topic coverage
- Associating Unemployment with Panic Attack Using Deep Learning during COVID-19 — shares topic coverage
- The Performance of Online Teaching for Flipped Classroom Based on COVID-19 Aspect — shares topic coverage
- Cultural Arts Tourism Business during the COVID-19 Pandemic (Case Study: Saung Mang Udjo, West Java, Indonesia) — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
16
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.